Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%.

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amid a complex narrative ...

though current valuations suggest the stock may be trading above its Fair Value. This comprehensive analysis delves into Eli Lilly's current position, recent financial results, product portfolio ...

With its 2-star rating, we believe Eli Lilly’s stock is over-valued compared to our long-term fair value estimate. We are maintaining our Eli Lilly fair value estimate at $580. Mounjaro and ...

It's next to impossible to predict what will happen in such a short period (by stock market standards). However, investors focused on the long game have nothing to fear. Eli Lilly remains an ...

Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th.